Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 621-630 of 639 results
J Hematol Oncol, 2020 • October 13, 2020
This study identifies MNPC, a dual inhibitor of NQO1 and GSTP1, as a potential therapeutic agent for glioblastoma (GBM). MNPC selectively inhibits the proliferation of GBM cells bearing the EGFRvIII m...
KEY FINDING: MNPC is a small molecule inhibitor that binds to both NQO1 and GSTP1 with high affinity and selectivity, inhibiting their enzymatic activities.
Pharmaceutics, 2021 • December 23, 2020
The study aimed to improve the bioavailability of Montelukast (MTK) by reformulating it into a mucoadhesive film for oral administration, addressing the limitations of existing tablet forms. A Phase 1...
KEY FINDING: The novel MTK film demonstrated significantly improved bioavailability compared to the marketed tablet in the clinical Phase 1a study.
Frontiers in Molecular Biosciences, 2020 • December 17, 2020
There are no marketed and effective antiviral drug products or biologics available for the control of SARS-CoV-2, other than symptomatic clinical treatment strategies for COVID-19. The LT receptor anta...
KEY FINDING: Leukotrienes (LTs), particularly cysteinyl-leukotrienes (Cys-LTs) and their receptors, are identified as potential drug targets in modulating various aspects of COVID-19 pathology, including inflammation, thrombosis, vascular damage, and fibrotic response.
Neurospine, 2020 • December 1, 2020
This review summarizes current knowledge on pharmacologic and regenerative cell therapies for spinal cord injury (SCI). It highlights the limitations of existing treatments and the need for further re...
KEY FINDING: Clinical studies of methylprednisolone for SCI have not shown clear benefits, and other drugs like Rho inhibitors and riluzole have also lacked significant positive outcomes.
Scientific Reports, 2021 • January 27, 2021
This study investigates the potential neuroprotective role of calcitonin gene-related peptide (CGRP) in diabetic peripheral neuropathy (DPN) using a rat model. The researchers found that dietary capsa...
KEY FINDING: Dietary capsaicin in diabetic rats preserved nociceptive sensation and CGRP levels in the spinal cord and DRG neurons.
Toxins, 2021 • January 5, 2021
The study purified and characterized BmK NSPK, a new scorpion toxin from Buthus martensii Karsch venom, identifying it as a potent potassium channel inhibitor. The research demonstrates that BmK NSPK ...
KEY FINDING: BmK NSPK directly inhibits outward K+ current without affecting sodium channel activities in spinal cord neurons.
Frontiers in Pharmacology, 2021 • January 27, 2021
This study investigates the therapeutic effect of systemic administration of FGF21 on spinal cord injury (SCI) in rats. The results demonstrate that FGF21 promotes functional recovery from SCI, protec...
KEY FINDING: Systemic administration of FGF21 significantly promoted the functional recovery of SCI in rats, as assessed by BBB scale and inclined plane test.
J Extracell Vesicles, 2020 • October 26, 2020
The development of EV therapeutics hinges on the ability to consistently produce EVs with reliable therapeutic efficacy, necessitating well-standardized assays. Functional assays, which evaluate the e...
KEY FINDING: Functional assays are crucial for assessing the molecular and physiological effects of EV preparations on target cells, organoids, organs, or organisms.
Scientific Reports, 2021 • March 1, 2021
This study demonstrates that tacrine and duloxetine, L1 mimetic compounds, exhibit beneficial effects in the peripheral and central nervous system of demyelinated zebrafish. The observed benefits incl...
KEY FINDING: Tacrine and duloxetine promote the regeneration of oligodendrocytes in the central nervous system after oligodendrocyte ablation in zebrafish.
PNAS, 2000 • July 5, 2000
The study investigates the physiological function of the kinin B1 receptor by generating mice with a targeted deletion of the B1 receptor gene. These mice are healthy and normotensive but show a blunt...
KEY FINDING: B1 receptor-deficient mice exhibited blunted hypotensive response to bacterial lipopolysaccharide.